A team of researchers has identified a method for treating particularly aggressive forms of breast cancer that could potentially save thousands of lives each year. According to results from a SWOG clinical trial those with tough-to-treat triple negative breast cancer whose tumors also don't allow for double-strand DNA repair fare better when treated with a common adjuvant breast cancer chemotherapy combination. The trial results showed that a well-established drug combination - adjuvant doxorubicin and cyclophosphamide (AC) chemotherapy - works well in this patient population. The results also showed the value of collecting and preserving cancer tumor tissue. University of Kansas
